The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha-2b plus ribavirin treatment of naïve and nonresponder chronic hepatitis C patients

Journal of Viral Hepatitis

Volumn 12, Issue 1, 2005, Pages 91-95

  Raptopoulou Gigi, Maria ^a,i   Tsantoulas, D ^b   Vafiadi, I ^c   Ketikoglou, I ^d   Paraskevas, E ^e   Vassiliadis, T ^f   Kanatakis, S ^g   Hatzis, G ^c   Sidiropoulos, L ^h   Akriviadis, E ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b SISMANOGLIO HOSPITAL   (Greece)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d HIPPOKRATION HOSPITAL   (Greece)

^e IASO GENERAL HOSPITAL   (Greece)

^f Aristotle University and Hippokration General Hospital   (Greece)

^g RED CROSS HOSPITAL   (Greece)

^h Loimodon Hospital   (Greece)

ⁱ NONE   (Greece)

Author keywords

Hepatitis C; Sustained virologic response; Treatment adherence

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ARTICLE; BLOOD TRANSFUSION; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; INTRAVENOUS DRUG ABUSE; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE;

ADULT; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; PATIENT COMPLIANCE; RIBAVIRIN;

EID: 19944434087     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2005.00549.x     Document Type: Article

References (16)

1. Davis GL, Ballart LA, Schiff ER et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501-1506.
2. Lindsay KL, Davis GL, Schiff ER et al. Response to higher doses of interferon alfa-2b in patients with chronic hepatitis C: a randomized multicenter trial. Hepatitis Interventional Therapy Group. Hepatology 1996; 24: 1034-1040.
3. Nakamura H, Ito H, Kamura Y et al. The importance of initiating daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: A multicenter randomized trial. Hepatogastroenterology 1998; 45: 1045-1055.
4. Tong CL, Reddy KR, Lee WM et al. Treatment of chronic hepatitis C with consensus interferon. A multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology 1997; 26: 747-754.
5. Poynard T, Marcellin P, Lee SS et al. International Hepatitis Interventional Therapy Group. Randomized trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-1432.
6. McHutchison JG, Gordon SC, Schiff ER et al. Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-1492.
7. de Lédinghen V, Trimouler P, Winnock M et al. French Multicenter Study Group. Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C. J Hepatol 2002; 36: 672-680.
8. de Lédinghen V, Trimouler P, Winnok M et al. French Multicenter Study Group. Daily or three times per week interferon a-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone. J Hepatol 2002; 36: 819-826.
9. Tassopoulos NC, Ketikoglou I, Tsantoulas D et al. A randomized trial to assess the efficacy of interferon alpha daily in combination with ribavirin in the treatment of naïve patients with chronic hepatitis C. J Viral Hepatitis 2003; 10: 383-389.
10. Tassopoulos NC, Tsantoulas D, Raptopoulou M et al. A randomized trial to assess the efficacy of interferon alpha in combination with ribavirin in the treatment of interferon alpha non-responders with chronic hepatitis C: superior efficacy of daily, high dosage of interferon-alpha in genotype 1. J Viral Hepatitis 2003; 10: 189-196.
11. McHutchison J, Poynard T, Harvey J, Garand JJ, Albercht JK. The International Hepatitis Therapy Group. The effect of dose reduction on sustained response in patients with chronic hepatitis C receiving interferon alfa 2b in combination with ribavirin. Hepatology 2000; 32: 4 (Pt 2).
12. McHutchison J, Manns M, Harvey J, Albrecht JK. Adherence to therapy enhances sustained response in chronic hepatitis C patients receiving Peg-Interferon alfa 2b plus ribavirin. J Hepatol 2001; 34 (Suppl. 1): 2-3.
13. Mchutchinson JG, Manns M, Patel K et al. Adherence to combination therapy enhances sustained response in genotype-1 infected patients with chronic hepatitis C. Gastroenterology 2002; 123: 1061-1063.
14. Golden A, Aubert RE, Dasmahapatra A. Improving compliance with combination therapy for patients with hepatitis C. Hepatology 2001; 34: 4 (Pt 2).
15. Wong JB, McHutchison JG, Manns MP et al. The clinical and economic cost of loss of adherence to ribavirin/PEG interferon alpha 2b for chronic hepatitis C. Gastroenterology 2002; 122: 4 (Abstract T1464).
16. Bernstein D, Kleinman L, Barker CHM, Revicki DA, Green J. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 2002; 35: 704-708.